Overview of ADC Payload-Linkers

According to Beacon H1 2024 ADC landscape review report[1], Since 2023, the ADC landscape grew by 21% in H1 2024, and keeping track of this landscape has never been more crucial. Topoisomerase I inhibitors have dominated the drug development market since 2023. The same trend has also been seen in newly-added drugs in H1 2024, topoisomerase I inhibitors account for 56% of the new drugs with disclosed payload, followed by tubulin inhibitors (27%). MMAE and Camptothecin are the two most common payloads used in new tubulin inhibitors and topoisomerase I inhibitors, respectively.

Source:https://beacon-intelligence.com/infographic/h1-2024-adc-landscape-review/ [1]

ChemExpress leads the field for ADC Payload-Linker and ADC conjugation. The following advantages empower us to provide better services to our clients in the ADC field, including:

• Over 80 payloads and 400 linkers in stock, 1000+ linker syntheses experience.

• 12 ADC payloads and related intermediates registered with the FDA DMF, including widely used payloads such as MMAE, Vc-MMAE, Exatecan, Eribulin, and morere.

• Supported clients with 5 projects in the preparation for the BLA submission for the past 12 months.

• 800+ existing ADC clients

• Over 10 years of experience

• Over 230 experienced ADC experts

• US FDA Inspection Concludes With Zero Observations

For more information,please download our ADC Payload-Linker Compounds Patent Analysis Report

You may also be interested in:

Exploring Out-Licensing Deals for Innovative ADC Drugs from China